Recent News for ANAB - AnaptysBio, Inc.

Date Title
May 8 AnaptysBio Started 2019 Quiet as a Ninja
May 7 AnaptysBio beats by $0.01
May 7 AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
May 1 Is AnaptysBio, Inc. (ANAB) A Good Stock To Buy?
May 1 AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
Apr 17 What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock
Apr 4 Will AnaptysBio Continue to Surge Higher?
Mar 12 Introducing AnaptysBio (NASDAQ:ANAB), The Stock That Dropped 42% In The Last Year
Mar 6 All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
Mar 4 AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
Feb 28 AnaptysBio beats by $0.27
Feb 28 AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
Jan 14 Why Biotech Investors Should Look At AnaptysBio
Jan 2 AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
Dec 21 The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Dec 20 H.C. Wainwright debuts new biotech buy list
Dec 20 Benzinga's Top Upgrades, Downgrades For December 20, 2018
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
Dec 19 The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
Dec 13 Hedge Funds Are Crazy About AnaptysBio, Inc. (ANAB)
Dec 4 Wedbush Moves To The Sidelines On Tesaro Following Glaxo Deal
Nov 26 Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Nov 21 Benzinga's Top Upgrades, Downgrades For November 21, 2018
Nov 19 Aimmune up 6% premarket on publication of successful late-stage study of peanut allergy candidate AR101

Back to the Main ANAB Page...